Fig. 1
Dose and time optimisation studies with streptozotocin (STZ) on the viability of RIN5F cells in vitro. (a) Effect of STZ on viability of RIN-5F cells. ┼P ≤ 0.02 and # P < 0.001 vs untreated control. (b) Effect of simultaneous -treatment with BDNF on STZ (20 mM)-induced toxicity to RIN5F cells. All values expressed as mean ± SEM. §P < 0.001 vs untreated control, **P < 0.01 vs STZ-treated group. *P < 0.001 vs respective untreated control (B = brain derived neurotrophic factor). All the above set of experiments were done in triplicate on three separate occasions (n = 9) and all values expressed as mean ± SEM (c) Measurement of BDNF (pg/ml) by ELISA in the supernatant of RIN5F cells treated with STZ using two different concentrations of STZ (20 and 40 mM) and at the end of two incubation periods (24 and 48 h). All values are expressed as mean ± SEM. *P < 0.001 compared to control. (d) Measurement of LXA4 (ng/ml) by ELISA in the supernatant of RIN5F cells treated with STZ (20 mM) and BDNF (100 ng/ml). All values are expressed as mean ± SEM. *P < 0.001 compared to control and STZ treatment. §P < 0.001 vs untreated control, *P < 0.001 vs STZ-treated group (e) and (f) Effect of STZ (20 mM)-induced changes in the mRNA expression of IkB-β; P65NF-κB; Bcl2; Bax; and Pdx in RIN5F cells. Cells were treated simultaneous with BDNF (100 ng/ml) and STZ for 24 h. IkB-β: §P < 0.001 vs untreated control P65NFκB: *P < 0.001 vs untreated control Bcl2: *P < 0.001 vs untreated control. Bax: §P < 0.05 vs untreated control; Pdx: *P < 0.001 compared to untreated control